TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.

Mehrnoosh Tashakori^1,2, Tapan Kadia³, Sanam Loghavi¹, Naval Daver³, Rashmi Kanagal-Shamanna¹, Sherry Pierce³, Dawen Sui⁴, Peng Wei⁴, Farnoosh Khodakarami⁵, Zhenya Tang¹, Mark Routbort¹, Carol A Bivins³, Elias J Jabbour³, L Jeffrey Medeiros¹, Kapil Bhalla³, Hagop M Kantarjian³, Farhad Ravandi³, Joseph D Khoury¹

¹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

²Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.

³Department of Leukemia, and.

⁴Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and.

⁵Cyclica Inc, Toronto, ON, Canada.

PubMed PMC DOI PDF

Abstract

Mutant TP53 is an adverse risk factor in acute myeloid leukemia (AML), but large-scale integrated genomic-proteomic analyses of TP53 alterations in patients with AML remain limited. We analyzed TP53 mutational status, copy number (CN), and protein expression data in AML (N = 528) and provide a compilation of mutation sites and types across disease subgroups among treated and untreated patients. Ou…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.